Gaudium IVF Delivers Record Q4FY26: Revenue, EBITDA and PAT

Gaudium IVF and Women Health Limited, a leading fertility and women's healthcare platform in India, today announced its Audited Financial Results for the quarter and financial year ended March 31, 2026.

Key Financial & Operational Highlights

- Q4 FY26 Revenue from operations stood at 30.35 Cr as against 26.92 Cr in Q4 FY25, a growth of 12.74% YoY; FY26 Revenue stood at X104.35 Cr as against X 70.72 Cr in FY25, a growth of 47.56% YoY - driven by higher patient volume at mature hub and high clinical success rate

- Q4 FY26 EBITDA stood at X12.17 Cr as against X8.72 Cr, a growth of 39.56% YoY, with EBITDA Margin at 40.10%; FY26 EBITDA stood at X37.70 Cr as against X 28.63 Cr in FY25, a growth of 31.69% YoY, with EBITDA Margin at 36.13% supported by operating leverage and a richer mix of advanced IVF protocols

- Q4 FY26 PAT stood at %8.36 Cr as against 26.45 Cr, an increase of 29.46% YoY, with PAT Margin at 27.54%; FY26 PAT stood at X24.48 Cr as against X 19.17 Cr in FY25, an increase of 27.69% YoY, with PAT Margin at 23.47%.

- In April 2026, Gaudium IVF became the first IVF chain in India to formally integrate Al-led embryology into routine clinical practice through a partnership with UK-headquartered IVF 2.0, deploying the SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) platforms.

The Company maintained its network of 7 hubs and 28 spokes in FY26, while delivering a strong clinical pregnancy success rate of 58% on the first IVF attempt.

Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF and Women Health Limited, said: "FY26 has been a defining year for Gaudium IVF, the year we transitioned into a listed, institutional and scalable fertility platform. Q4 capped this journey with steady patient volumes across our mature centres and continued discipline on cost, which together translated into the growth you see in revenue, EBITDA and PAT for the quarter and the year.

IVF Treatment remains the engine of the business and will continue to anchor revenue, supported by our 58%-plus clinical success rate in first attempt. The Pharmacy vertical, operated through our subsidiary, is a smaller part of the business and we expect it to remain so. Our 15-bed Hospital facility at Janakpuri rounds off the patient journey from fertility treatment to delivery and post-natal care, a continuum few peers in the listed space offer today.

Looking ahead, our priority is execution. Of the 19 new IVF hubs planned under our IPO use-of-proceeds, 3 hubs are expected to be operational soon, with the balance under Phase 1 - taking the total to 10 in FY27, to follow, alongside 8 in FY28 and 1 in FY29. This will take us deeper into Tier-Il markets while reinforcing existing metro hubs with additional spokes. Alongside physical expansion, we are doubling down on technology: in April we became the first IVF chain in India to adopt Al-led embryology with the SiD and ERICA platforms in partnership with IVF 2.0, and we expect this to meaningfully improve embryo selection consistency, reduce repeat cycles and strengthen patient confidence. With a debt-light balance sheet postIPO, a clearly funded expansion plan, and an underpenetrated Indian fertility market, we believe Gaudium IVF is well placed to compound growth responsibly over the coming years."

Source : Equity Bulls

Keywords

GaudiumIVRandWomenHealth Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate